Hormone treatment resistance in ER+ breast cancer
ER+ breast tumours undergo genome-wide epigenetic alterations, and we have previously shown that enhancer methylation results in oncogenic estrogen signalling (published in Fleischer et al., Genome Biol 2014, Fleischer & Tekpli et al., Nat Commun 2017, and Ankill et al., NAR Cancer 2022).
Altered DNA methylation and chromatin interactions are crucial in the development of resistance to hormone therapy; a key treatment plan for post-menopausal ER+ breast cancer patients. We aim to identify and characterize treatment resistance-driving epigenetic alterations found in human breast tumour samples using single-cell ATAC-seq. Single-cell ATAC-seq explores the evolving epigenetic landscapes of both tumour and non-tumour cell populations of a patient biopsy (Figure 1), offering novel insight into cell biology, disease etiology and treatment response.